TL;DR
Among popular immune-support options, evidence quality varies sharply. Topical zinc has real placebo-controlled trial support for cold sores. L-lysine has been tested in multiple trials, but a 2015 Cochrane review of 32 trials found no evidence it prevents outbreaks. Vitamin D has only an observational link. Monolaurin and oral zinc remain mechanism-only, with no human outbreak trial for either.
Key Takeaways
- Only topical zinc sulfate has been tested against herpes labialis in multiple placebo-controlled human trials with a generally favorable, though modest, result.
- L-lysine has the most human trial data of any option here, but a 2015 Cochrane systematic review of 32 randomized trials found no evidence it prevents cold sore recurrence, even though several smaller individual trials reported benefit.
- Vitamin D’s connection to herpes recurrence comes from one observational study linking low levels to more frequent outbreaks; no trial has tested whether supplementing actually reduces recurrence.
- Monolaurin’s evidence for herpes is entirely in vitro: lauric acid and related monoglycerides inactivate HSV-1 on contact in lab conditions, but no published human trial has tested oral monolaurin for outbreak frequency or severity.
- Popularity and evidence quality don’t move together here; some of the most recommended options have the thinnest human data, and that’s worth knowing before building a routine around any one of them.
Search “immune support for herpes” and the same four names show up everywhere: vitamin D, zinc, lysine, monolaurin. What’s harder to find is a straight answer about which of these actually has human evidence behind it, and which is popular mostly because it sounds plausible.
Those are genuinely different categories, and mixing them up is easy to do. This piece sorts the four by evidence level, clinical trial, observational, or mechanism only, and explains what each level actually means before walking through the studies themselves.
How Should You Read “Evidence” for a Supplement?
Three tiers show up repeatedly in this space, and they’re not interchangeable. Clinical trial evidence means the supplement was given to real people, usually against a placebo, and outcomes were measured directly. Observational evidence means researchers noticed a pattern, like people with more outbreaks tending to have lower levels of something, without ever testing whether changing that level changes anything. Mechanism-only evidence means a compound does something interesting to the virus in a lab dish or animal model, which is real and worth knowing, but hasn’t been tested in people with the condition at all.
A compound can have a fascinating mechanism and still fail every human trial, and a compound can work in practice without anyone fully understanding why. Knowing which tier a claim sits in is what actually lets you weigh it.
Comparing the Evidence
| Supplement | Evidence Level | What the Research Actually Shows |
|---|---|---|
| Zinc (topical) | Clinical trial | Placebo-controlled trials found topical zinc sulfate reduced symptom severity and sped healing in recurrent herpes labialis |
| Zinc (oral) | Mechanism only | Zinc supports antiviral immune function broadly, studied mainly in other viral illnesses; no published human trial tests oral zinc for herpes outbreak frequency |
| L-lysine | Clinical trial, mixed | Multiple small RCTs conflict; the most rigorous synthesis (Cochrane, 32 trials) found no evidence of preventive efficacy |
| Vitamin D | Observational | Low serum vitamin D was significantly associated with recurrent herpes labialis in a case-control study; no supplementation trial exists |
| Monolaurin | Mechanism only (in vitro) | Lauric acid and related monoglycerides inactivate HSV-1 on contact in lab testing; no published human trial on oral monolaurin and outbreak frequency |
Zinc: Real Trial Evidence, But Only for the Topical Form
Topical zinc has the cleanest trial support of anything on this list, with an important caveat: it’s specifically the topical form, applied directly to a lesion, not an oral supplement. A placebo-controlled double-blind trial of topical zinc sulfate gel for recurrent herpes labialis found significantly less severe symptoms and faster healing than the gel base alone (Kneist et al., 1995, PMID: 7612066). A broader review of herpes labialis treatments confirmed this pattern, describing topical zinc creams as having a “small favourable effect” on symptom duration when applied promptly, at a similar level of evidence to topical antiviral creams (Opstelten et al., 2008, PMC2602638).
Oral zinc is a different story. Zinc’s role in general antiviral immune function is well documented, including research on how zinc deficiency impairs immune responses to viral infection (Asl et al., 2021, doi:10.1016/j.intimp.2021.107630), but that research comes almost entirely from other viral contexts. No published trial has tested oral zinc supplementation specifically for herpes outbreak frequency or severity, which makes it a mechanism-only claim when applied to herpes specifically, however solid the general immune-function research is.
L-Lysine: The Most-Studied Option, and the Most Contested
L-lysine has more human trial data behind it than anything else on this list, and that’s exactly why its story is complicated rather than simple. Individual trials genuinely disagree with each other. A six-month trial using 3,000 mg of L-lysine daily found significantly fewer recurrences, milder symptoms, and faster healing compared to placebo (Griffith et al., 1987, PMID: 3115841). Another trial found a dose-dependent effect: 1,248 mg daily reduced recurrence, but 624 mg daily did not (McCune et al., 1984, PMID: 6435961), while a separate study tied benefit to reaching a specific serum lysine concentration rather than dose alone (Thein & Hurt, 1984, doi:10.1016/0030-4220(84)90030-690030-6)). Against that, a placebo-controlled trial using 1,200 mg daily found no substantial benefit for either treating active episodes or preventing recurrence (DiGiovanna & Blank, 1984, PMID: 6419679).
When all of this gets pooled together at the highest level of scrutiny, the picture shifts further. A 2015 Cochrane systematic review covering 32 randomized trials and 2,640 participants across 19 different prevention strategies concluded there was no evidence of efficacy for lysine in preventing herpes labialis recurrence (Chi et al., 2015, doi:10.1002/14651858.CD010095.pub2). That’s a notably more skeptical conclusion than some individual trials suggest, and not every later review agrees with it. A 2021 dermatology review, for instance, described lysine as effective for prophylaxis specifically, while agreeing it doesn’t shorten active lesions (Jamgochian et al., 2021, PMC9830249). This is a live disagreement in the literature, not a settled question, which is a meaningfully different situation than “lysine is proven” or “lysine doesn’t work.” For more on how lysine and arginine intake fit into daily eating patterns, this site’s guide on diet and herpes covers the practical side in more depth.
Vitamin D: A Real Association, Not Yet a Tested Intervention
Vitamin D’s evidence for herpes sits squarely in the observational tier, and it’s worth being precise about what that does and doesn’t mean. A case-control study comparing people with recurrent herpes labialis to healthy controls found significantly lower average serum vitamin D levels in the group with recurrent outbreaks, with the vast majority of the entire study population showing some degree of deficiency (Öztekin & Öztekin, 2019, doi:10.1089/vim.2019.0013).
That’s a genuine, statistically significant pattern, but it’s an association, not a test of cause and effect. It doesn’t establish that people with recurrent outbreaks are deficient because of the outbreaks, that low vitamin D contributes to outbreaks, or that correcting a deficiency through supplementation would change recurrence at all. No published trial has given people vitamin D and measured whether their herpes recurrence changed, which is the study that would actually answer the question this observation raises.
Monolaurin: A Compelling Mechanism, Without a Human Trial to Match
Monolaurin’s evidence here is the most mechanism-heavy of the four. Lab research testing lauric acid and related monoglycerides directly against HSV-1 found they inactivated the virus on contact, causing more than a 100,000-fold reduction in viral titer within minutes at sufficient concentration, in the context of a topical virucidal formulation rather than an ingested supplement (Kristmundsdóttir et al., 1999, doi:10.1021/js9900396). That’s a real, measurable effect, and it’s consistent with monolaurin’s known ability to disrupt the lipid envelope that HSV-1 depends on.
What doesn’t exist yet is a published human trial testing oral monolaurin supplementation against herpes outbreak frequency or severity. The gap between “inactivates the virus in a lab dish or on contact” and “reduces outbreaks when taken as a daily oral supplement” is exactly the gap that human trials are designed to close, and for monolaurin and herpes specifically, that trial hasn’t been run. This site’s deeper look at what the monolaurin research does and doesn’t show covers the broader mechanism research in more detail.
Frequently Asked Questions
Which supplement has the strongest evidence for herpes outbreaks?
Topical zinc sulfate has the most consistent placebo-controlled trial support, though specifically for symptom severity and healing time on active lesions, not for preventing future outbreaks. It’s also the most narrowly studied, tested as a topical application rather than an oral supplement.
Does the Cochrane review mean lysine definitely doesn’t work?
Not definitively, but it does mean the most rigorous available synthesis of the trial evidence found no proof of a preventive effect, even though some individual trials reported benefit. Reasonable experts have read the same evidence differently, which is why this remains an open question rather than a closed one.
Is vitamin D deficiency a cause of herpes outbreaks?
That hasn’t been established. One study found people with recurrent outbreaks tend to have lower vitamin D levels on average, but that kind of observational finding can’t determine whether the deficiency causes more outbreaks, results from them, or reflects some other shared factor.
Why does monolaurin have so little human research if the lab findings are so consistent?
Promising lab and mechanism findings don’t automatically lead to funded human trials, particularly for a compound available as an unpatented supplement rather than a drug with commercial backing for clinical development. The mechanism research is real; it simply hasn’t yet been tested in the specific way that would confirm an effect on outbreak frequency in people.
Should I stop taking any of these if the evidence is weak?
That’s a personal and medical decision, not something this comparison is positioned to answer. What’s useful here is knowing which claims rest on human trials, which rest on associations, and which rest on lab mechanisms only, so any decision is made with an accurate picture of what’s actually been shown.
Summary
Evidence quality and popularity don’t track together in this space. Topical zinc has the cleanest trial support, but only for a narrow use. Lysine has the most human data of the four, yet the most rigorous review available found no proof it prevents outbreaks, leaving real disagreement in the literature. Vitamin D has a genuine but unproven association. Monolaurin has a compelling, consistent mechanism with no human outbreak trial behind it yet.
None of that means any of these are worthless, only that “has research behind it” and “has been proven to reduce outbreaks in people” are different claims, and it’s worth knowing which one is actually being made. For readers evaluating monolaurin supplement quality specifically, Shop Monolaurin is a reasonable place to start comparing options. This content is educational and doesn’t replace guidance from a healthcare provider familiar with your specific situation.
Continue Exploring
- Diet and Herpes: Lysine, Arginine, and Evidence-Based Meal Strategies
- Does Monolaurin Really Work? What Science Says About Its Antiviral Benefits
- Herpes Outbreak Prevention Diet: Best Foods to Eat (and Avoid) for Immune Balance
References
- Kneist, W. et al., “Clinical double-blind trial of topical zinc sulfate for herpes labialis recidivans,” Arzneimittel-Forschung, 1995. https://pubmed.ncbi.nlm.nih.gov/7612066/
- Opstelten, W. et al., “Treatment and prevention of herpes labialis,” Canadian Family Physician, 2008. https://pubmed.ncbi.nlm.nih.gov/19074705/
- Asl, S.H. et al., “Immunopharmacological perspective on zinc in SARS-CoV-2 infection,” International Immunopharmacology, 2021. https://doi.org/10.1016/j.intimp.2021.107630
- Griffith, R.S. et al., “Success of L-lysine therapy in frequently recurrent herpes simplex infection,” Dermatologica, 1987. https://pubmed.ncbi.nlm.nih.gov/3115841/
- McCune, M.A. et al., “Treatment of recurrent herpes simplex infections with L-lysine monohydrochloride,” Cutis, 1984. https://pubmed.ncbi.nlm.nih.gov/6435961/
- Thein, D.J. & Hurt, W.C., “Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis,” Oral Surgery, Oral Medicine, and Oral Pathology, 1984. https://doi.org/10.1016/0030-4220(84)90030-690030-6)
- DiGiovanna, J.J. & Blank, H., “Failure of lysine in frequently recurrent herpes simplex infection,” Archives of Dermatology, 1984. https://pubmed.ncbi.nlm.nih.gov/6419679/
- Chi, C.C. et al., “Interventions for prevention of herpes simplex labialis (cold sores on the lips),” Cochrane Database of Systematic Reviews, 2015. https://doi.org/10.1002/14651858.CD010095.pub2
- Jamgochian, M. et al., “Diet in Dermatology: Review of Diet’s Influence on the Conditions of Rosacea, Hidradenitis Suppurativa, Herpes Labialis, and Vitiligo,” American Journal of Lifestyle Medicine, 2021. https://pubmed.ncbi.nlm.nih.gov/36636389/
- Öztekin, A. & Öztekin, C., “Vitamin D Levels in Patients with Recurrent Herpes Labialis,” Viral Immunology, 2019. https://doi.org/10.1089/vim.2019.0013
- Kristmundsdóttir, T. et al., “Development and evaluation of microbicidal hydrogels containing monoglyceride as the active ingredient,” Journal of Pharmaceutical Sciences, 1999. https://doi.org/10.1021/js9900396